Isomorphic Labs has raised $7.7 billion with no drug yet in human trials.

Its oncology and immunology programmes show positive preclinical results only, the company says.

Greenoaks and Sequoia led the $5 billion round, with Alphabet, Abu Dhabi’s MGX and Temasek returning.

Isomorphic says it is preparing its first candidates for clinical trials.

How each outlet framed it
Zhidx leans favorable
tallies Isomorphic's $7.7bn cumulative funding and lists its investor roster, including Greenoaks, Sequoia and a16z

Sources: Zhidx